The Drug Enforcement Agency announced last Friday that the temporary rule “Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications” (RIN 1117-ZA06) will extend telemedicine prescribing of Schedule II-V medications, including as Adderall, Buprenorphine, and Ketamine, without in-person evaluations through December 31, 2025. This extends the COVID-era waiver, first implemented in March 2020, to over five years. The extension included no new restrictions.
